New advances in the study of clinical therapy for hepatitis C!

October 5, 2020 at 17:30 P.M. Beijing time, the 2020 Nobel Prize in Physiology or Medicine was announced, from Harvey J. Alter of the National Institutes of Health, Michael Houghton of the University of Alberta in Canada and Charles M. Rice of Rockefeller University in the United States for the discovery of the hepatitis C virus.
so in recent years scientists in the field of hepatitis C clinical therapy research has made what important research results, this paper small editor on the relevant research results to organize, share with you! Photo credit: PRESSENZA1 Pediatric Hepatitis C Drug! Gilead's "Ji-San" Epclusa is approved by the European Union for the use of ≥ 6-year-olds ≥ 17 kg! News read: EU OKs paediatric use of Gilead's Epclusa Gilead Science (Chinese commodity name: proponsa, generic name: Sophosbuvir/Vipatave, sofosbuvir/velpatasvir, 400mg/100mg tablets) Recently in the EUROPEAN Union regulatory good news! The European Commission (EC) has approved the expansion of Epclusa's marketing mandate for the treatment of chronic hepatitis C paediatric patients aged ≥6 years and weighing ≥17 kg, regardless of HCV genotype or severity of liver disease.
A Gilead Science spokesman said Epclusa is a pan-genotype, pan-fibrosis treatment that simplifies the choice of suitable treatment options, eliminates the need for some pre-treatment assessments, and minimizes the time from diagnosis to treatment and cure.
, Epclusa was approved by the FDA in March 2020 for the same pediatric population.
medication, Epclusa's recommended dose ≥ 6-year-olds is based on weight and liver function.
it is worth noting that Epclusa is the first generic, protease-free inhibitor treatment approved for the treatment of adult and child patients with hepatitis C.
2: China's new hepatitis C drug! The full oral hepatitis C treatment program RDV/DNV (Ravi Davy/Dano River) was approved, with a 12-week cure rate of ≥99%! Ascletis recently announced that its full oral hepatitis C treatment has been approved for listing by China's State Drug Administration (NMPA).
this full oral hepatitis C treatment (RDV/DNV treatment) was developed by Ravi Dawe (New Lilly? United Dano Reeve (Gonoway? composition.
Phase II/III clinical trials completed in China showed that after 12 weeks of treatment, the RDV/DNV treatment program had a cure rate (SVR12) of 99% in patients with non-hepatic cirrhosis type 1, and SVR12 was achieved 100% in patients with NS5A resistance mutations at baseline.
and Dano Riveri are supported by the national 13th Five-Year Plan "major new drug creation" science and technology projects.
2014, Goliath acquired an exclusive interest in Greater China from Presidio.
Presidio is a pharmaceutical company in the clinical stage.
3: Simplify hepatitis C treatment! AbbVie Maviret has been approved by the European Union, the only pan-genotype 8-week program, has been listed in China! News read: European Commission Grants AbbVie Marketing Authorization Shortening MAVIRET? (glecaprevir/ pibrentasvir) Treatment Duration to Eight Weeks for Treatment-Na? Ve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis AbbVie recently announced that the European Commission (EC) has approved the generic hepatitis C therapy Maviret (Chinese commodity name: Enochan, generic name: Gkarive plentawe, The marketing authorization of glecaprevir/pibrentasvir has been changed to reduce the treatment plan for patients with genotype 3 (GT 3) chronic hepatitis C (HCV) who are treated with primary treatment (treatment-naive) and accompaniment cirrhosis from 12 weeks to 8 weeks per day.
, Maviret's symptoms in the EU were: (1) as an 8-week, generic genotype (GT 1-6), once-a-day programme for first-treatment HCV patients without cirrhosis; Program for GT 1, 2, 4, 5, 6 HCV patients with primary treatment and accompaniment cirrhosis, and (3) In patients with GT3 for primary treatment and compensation cirrhosis, Maviret recommended a treatment plan of 12 weeks.
this approval makes Maviret the only generic genotype (GT 1-6) 8-week treatment option in the European Union for the treatment of patients with initial, companion or non-complicity cirrhosis HCV, regardless of genotype.
end hepatitis C! Gilead "Ji four generations" Vosevi - pan-genotype hepatitis C rescue therapy was approved, all four generations of products are available in China! News read: China National Medical Products Administration Approves Vosevi? (Sofosbuvir, Velpatasvir and Voxilaprevir) for People With Chronic Hepatitis C Infection Who Ask Re-Treatment hepatitis C treatment absolute overlord Gilead recently announced that China's State Drug Administration (NMPA) has approved the general Genotype three-in-one hepatitis C treatment drug Vosevi ("Ji Si generation", sofosbuvir/velpatasvir/voxilaprevir, SOF/VEL/VOX, sophosphobwe/Vipatawe/Vosserive, 400mg/100mg), the drug is a daily oral monopicide solution for previous failures with a direct-acting antiviral (DAA) therapy, Retreatment (re-treatment) of adults infected with chronic hepatitis C virus (HCV) without cirrhosis or with prosaic cirrhosis.
is the fourth most common infectious disease in China, with about 10 million people infected with hepatitis C.
HCV genotypes 1, 2, 3, 6 accounted for more than 96% of all cases.
Vosevi's approval in China means that more people with incurable chronic HCV now have another chance to heal, representing another important step forward in achieving the public health goal of eliminating the hepatitis C virus in China and around the world.
5: New hepatitis C drug! Gileadji III Epclusa approved by Japan for treatment of hepatitis C 1-6 News Read: Japan's Ministry of Health, Labour and Welfare Approves Gilead's Epclusa? (Sofosbuvir/Velpatasvir) Hepatitis C treatment giant Gilead recently announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Epclusa (sofosbuvir 400mg/velpatasvir 100) mg) for treatment: (1) adult infection with chronic hepatitis C virus (HCV) accompanied by uncompensated cirrhosis of the liver;
, so far, no treatment options have been approved in Japan for patients with hepatitis C who have lost compensation for liver cirrhosis, and there are limited treatment options for patients with hepatitis C who have received DAA treatment.
approval of Epclusa will provide a new treatment option for these two groups of retrendable hepatitis C.
Dr. John McHutchison, Chief Scientific Officer and Head of Research and Development at Gilead Sciences, said, "Gilead continues to develop new HCV therapies to help all HCV patients get a cure and ultimately to help eradicate hepatitis C disease worldwide.
in Japan, patients with hepatitis C who have lost their liver cirrhosis or who have previously received hepatitis C medication but have not been cured have few treatment options.
we are pleased to launch Epclusa in Japan to meet the significant medical needs that exist in this market.
" Photo Source: es.wikipedia.org 6: New Chinese hepatitis C drug! Gileadji II Harvoni (Xia Fanning) approved by China for treatment of hepatitis C 1-6 News Read: China's National Medical Products Administration Approves Harvoni? (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6 U.S. pharmaceutical giant Gilead recently announced that China's National Drug Administration (NMPA) has approved the hepatitis C compound drug Harvoni Fanning, ledipasvir/sofosbuvir, 90mg/sophosphobwe 400mg for the treatment of adults infected with chronic hepatitis C virus (HCV) type 1-6 and adolescents aged 12-18 years.
hepatitis C is a major public health challenge.
estimates that nearly 10 million people in China suffer from chronic hepatitis C, about 58 percent of whom are infected with HCV type 1.
approval of Harvoni will provide a single tablet (STR) with high efficacy, short course of treatment and generic genotype for the hepatitis C patient population in China.
harvoni is based on data from an open-label Phase IIIb clinical study.
the study, conducted at Chinese mainland 18 research centres from May 2016 to July 2017, assessed the efficacy and safety of Harvoni's 12-week programme for the treatment of 206 patients with hepatitis C 1, including those who had not been treated in the past (first treatment), had been treated (treated), had no cirrhosis or had prosaic cirrhosis.
results show that Harvoni's virological cure rate (SVR12) for the 12-week program is 100%.
most common adverse reactions (≥10%) in recent studies include viral upper respiratory tract infections and upper respiratory tract infections.
the latest news on hepatitis C! AbbVie Pan Genotype Therapy Mavyret 8-Week Program treatment for insolmental cirrhosis hepatitis C virology cure rate of up to 100% News Read: AbbVie's MAVYRET? (glecaprevir/ pibrentasvir) Shows High Virologic Cure? Ve Hepatitis C Patients with Compensated Cirrhosis U.S. biotech giant AbbVie recently unveiled new phase II CLINICAL data for the treatment of the pangene-type hepatitis C drug Mavyret (glecaprevir/pibrentasvir, G/P) in patients with pre-treatment (untreated) treatment at the 69th Annual Meeting of the American Society for The Study of Hepatology (AASLD) in San Francisco, USA.
EXPEDION-8 is an ongoing non-randomized, one-arm, open-label, multi-center PHASE IIIb study designed to assess the efficacy and safety of Mavyret in patients with the primary and prosaic cirrhosis genotype 1-6C.
The study included two queues: queue 1 for patients with genotype 1, 2, 4, 5, 6 C (n- 280) with prospication cirrhosis, and queue 2 for patients with genotype 3 C with prosotic cirrhosis.
of the 280 patients in the
queue 1 group, 7 were excluded from the SVR12 analysis (n=273), of which 5 were due to loss of follow-up and 2 were due to less than 8 weeks of treatment (one of which reached SVR12).
8: AbbVie Jianle? (Obi-Parry Film) United Ichiri? (Dasebwe sodium tablets) 8 weeks of new treatment in China approved<!-- / ewebeditor: page-><!--ewebeditor: title" - > the world's leading biopharmaceutical company AbbVie announced today, Vi jianle? (Obi-Parry Film) United Ichiri? On March 2, 2018, the hepatitis C treatment plan was approved by China's State Food and Drug Administration (CFDA) for the treatment of patients with chronic hepatitis C with gene type 1b, primary treatment, mild to moderate hepatitis C (F0-F2), which can be shortened to 8 weeks, and is the first approved 8-week treatment program in China.
is the second breakthrough the program has made in less than half a year since it was approved for listing in China in September 2017.
this solution is full oral, non-interferon, contains 3 direct antiviral drugs, can target the HCV life cycle of 3 main targets, inhibit the replication of HCV.
"Vi Jianle?" And Ichiri? The eight-week new treatment was approved in China, once again reflecting AbbVie's hepatitis C in China.